NYU Langone Medical Center
New York, 10016, United States
NCT Number: NCT02287701
The overarching goal of this project is to explore whether associations exist between metrics obtained from PET/MRI incorporating advanced MRI sequences and features of bladder cancer, including grade, stage, and treatment response.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New York, 10016, United States
The investigators will assess an advanced non-Gaussian diffusion-weighted imaging (DWI) model termed diffusion kurtosis imaging, multi-echo T2 mapping, dynamic contrast-enhanced (DCE) MRI using a motion-robust high-temporal and high-resolution radial acquisition scheme employing compressed sensing, and simultaneously acquired 18-fluoro (18F)- fluorodeoxygluclose (FDG) data. Preliminary data demonstrates the investigators ability to execute and evaluate all of these techniques at the investigators center. The investigators hypothesize that these techniques will be sensitive to functional and metabolic differences between subsets of bladder cancer cases and will improve upon the performance of current imaging protocols in bladder cancer characterization. Moreover, the investigators believe that these techniques will provide complementary information, such that they may be combined in a synergistic fashion for bladder cancer evaluation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Simultaneous PET/MRI (3T system)
Other names: Siemens Biograph mMR
Time frame: within one week of study completion
The tumor SUV value obtained approximately one hour following 18-fluorodeoxyglucose administration will be measured.
NYU Langone Health
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03924856
Bladder Cancer, Female Urogenital Diseases
La Jolla, California, United States
View Trial DetailsNCT04081246
Bladder Cancer, Bladder Neoplasm
Hong Kong
View Trial DetailsNCT05512377
Biliary Tract Cancer, Biliary Tract Diseases
Mobile, Alabama, United States
View Trial DetailsNCT06955910
Behavior, Behavioral Symptoms
Padova, Italy/Padova, Italy
View Trial Details